amiodarone has been researched along with Gout in 1 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Positive control was amiodarone and thyroxine, as a marker of amiodarone-induced hypothyroidism, a known adverse event with a clear temporal relationship to amiodarone initiation." | 3.81 | Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. ( Chan, EW; Choi, NK; Kao Yang, YH; Kimura, M; Kimura, T; Kubota, K; Lai, EC; Man, KK; Ooba, N; Park, BJ; Pratt, N; Roughead, EE; Sato, T; Shin, JY; Wong, IC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pratt, N | 1 |
| Chan, EW | 1 |
| Choi, NK | 1 |
| Kimura, M | 1 |
| Kimura, T | 1 |
| Kubota, K | 1 |
| Lai, EC | 1 |
| Man, KK | 1 |
| Ooba, N | 1 |
| Park, BJ | 1 |
| Sato, T | 1 |
| Shin, JY | 1 |
| Wong, IC | 1 |
| Kao Yang, YH | 1 |
| Roughead, EE | 1 |
1 other study available for amiodarone and Gout
| Article | Year |
|---|---|
Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries.
Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Analysis of Variance; Asia; Australia; Chi-Squa | 2015 |